Search - tctmd.com

Displaying 381 - 400 of 603

Sort: Relevancy | Date

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

‘Nontraditional’ CAC, CRP, or ABI Risk Tools Not Recommended, Says USPSTF

News Daily News

‘Nontraditional’ CAC, CRP, or ABI Risk Tools Not Recommended, Says USPSTF

January 17, 2018

Using Multiple Arterial Grafts Appears to Improve CABG Outcomes

News Daily News

Using Multiple Arterial Grafts Appears to Improve CABG Outcomes

December 20, 2017

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

News Daily News

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

December 11, 2017

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

News Conference News AHA 2017

Global Improvement in ACS Care Seen With Regional Clinical Pathway Implementation

Yael L. Maxwell

November 27, 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

News Conference News AHA 2017

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

November 11, 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

November 01, 2017

Debate: With Improved Technology and Optimal Technique ABSORB Will Become a Widely Used Device

Presentation TCT 2017

Debate: With Improved Technology and Optimal Technique ABSORB Will Become a Widely Used Device

Presenter: Stephen G. Ellis, Takeshi Kimura, Hiram G. Bezerra

October 31, 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

REVASCTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

News Conference News TCT 2017

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

October 31, 2017

Long-term Absorb BVS Data Continue to Disappoint

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.